Skip to main content
Fig. 5 | Gut Pathogens

Fig. 5

From: Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets

Fig. 5

Amplicon sequence variants (ASVs) as biomarkers for predicting clinical remission at week 8. A Different 48 ASVs were identified by comparing baseline samples of week-8 remitters vs non-remitters (Linear discriminant analysis score 2.0). B Bar graph of the positive and negative ASVs related to remission to adalimumab (ADA) treatment in patients with ulcerative colitis (UC). The positive and negative ASVs were included in the 48 different ASVs shown in A. The positive ASVs were the ASVs highly found in the samples with a clinical remission shown in the upper part of the heat map, and the negative ASVs were found in the samples of non-remitters shown at the bottom of the heat map. Each bar represents the value obtained by the log ratio of the average relative abundance of positive ASVs/average relative abundance of negative ASVs. C The receiver operating characteristic curve (ROC-curve) based on the log ratio of Avg. relative abundance of positive ASVs/Avg. relative abundance of negative ASVs. Using the ROC function in the Epi package in the R v4.0.2, the ROC curve was plotted with the area under the curve (AUC)

Back to article page

Gut Pathogens

ISSN: 1757-4749